Press Release: Belite Bio Presents Additional Analysis From Phase 2 Study of Tinlarebant in Stargardt Disease at the ARVO Annual Meeting
Press Release: Belite Bio Presents Additional Analysis From Phase 2 Study of Tinlarebant in Stargardt Disease at the ARVO Annual Meeting
新聞稿：Belite Bio在ARVO年會上公佈了Tinlarebant治療Stargardt病的2期研究的更多分析
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登入免費觀看全文
登入/註冊